Document Detail


Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
MedLine Citation:
PMID:  19996579     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Previously an increased frequency of KIT aberrations in mucosal melanomas was reported, whereas c-KIT in most types of cutaneous melanomas does not appear to be of pathogenetic importance. Imatinib has become the standard of care in other cancers with KIT mutations such as gastrointestinal stromal tumors. Recently 12 cases of metastatic melanoma and KIT-activating mutations have been published to be successfully treated with c-KIT blockers such as imatinib, sunitinib, dasatinib or sorafenib. We report here on one of our patients with KIT-activating mutation in metastatic anal mucosal melanoma, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.
Authors:
Imke Satzger; Uta K?ttler; Bernward V?lker; Florian Schenck; Alexander Kapp; Ralf Gutzmer
Related Documents :
18570719 - Incidental seminal vesicle smooth muscle neoplasm of unknown malignancy following robot...
7637119 - Lower extremity lymphedema caused by acquired immune deficiency syndrome-related kaposi...
7889669 - Agminate spitz naevi arising on hyperpigmented patches.
16981999 - Uncommon sarcomas of the uterine cervix: a review of selected entities.
22493579 - Omalizumab for chronic urticaria: a case series and overview of the literature.
15569649 - Extraskeletal ewing's sarcoma of the parapharyngeal space.
12534129 - Imported viral haemorrhagic fever with a potential for person-to-person transmission: r...
24995189 - Multicentric aggressive mammary fibromatosis with cytological features and review of li...
15020729 - Underreporting of fatal occupational injuries in catalonia (spain).
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2009-12-09
Journal Detail:
Title:  Dermatology (Basel, Switzerland)     Volume:  220     ISSN:  1421-9832     ISO Abbreviation:  Dermatology (Basel)     Publication Date:  2010  
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-04-12     Revised Date:  2010-06-16    
Medline Journal Info:
Nlm Unique ID:  9203244     Medline TA:  Dermatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  77-81     Citation Subset:  IM    
Copyright Information:
Copyright 2009 S. Karger AG, Basel.
Affiliation:
Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany. satzger.imke @ mh-hannover.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Agents / therapeutic use*
Anus Neoplasms / drug therapy*,  secondary
Female
Humans
Melanoma / drug therapy*,  genetics,  secondary
Mucous Membrane / drug effects,  pathology
Mutation
Piperazines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins c-kit / antagonists & inhibitors,  genetics
Pyrimidines / therapeutic use*
Skin Neoplasms / genetics,  pathology*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 152459-95-5/imatinib; EC 2.7.10.1/Proto-Oncogene Proteins c-kit

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Smoking and Alcohol Intake in Severely Affected Patients with Psoriasis in Germany.
Next Document:  Immune reactivity and attractiveness.